Phagenesis

Executive Summary

Phagenesis is a UK-based medical device company addressing a critical unmet need in post-stroke care: dysphagia, or swallowing difficulty, which affects over 50% of stroke survivors and leads to serious complications like aspiration pneumonia, malnutrition, and prolonged hospitalization. The company's flagship product, the Phagenyx® System, delivers pharyngeal electrical stimulation (PES) via a nasogastric tube to retrain the brain's swallowing control centers. Designed for rapid, bedside intervention, the system accelerates recovery of swallowing function, reduces tube feeding dependency, and lowers healthcare costs. With a strong clinical evidence base including published randomized controlled trials, Phagenesis is well-positioned to become the standard of care for neurogenic dysphagia. The global market for dysphagia management is significant, driven by aging populations and rising stroke incidence. The company is privately held and has secured CE marking under the Medical Device Regulation, with ongoing efforts to expand into the U.S. market via FDA clearance. Commercial traction in Europe and partnerships with leading stroke centers underscore growing adoption. Phagenesis represents a compelling investment opportunity in the neurostimulation and medical device space, with potential for transformative impact on patient outcomes and healthcare economics.

Upcoming Catalysts (preview)

• Q3 2026FDA Premarket Approval (PMA) Decision for Phagenyx System70% success
• Q2 2026Publication of Pivotal U.S. Clinical Trial Results85% success
• Q4 2026Strategic Distribution Partnership for U.S. Market Entry60% success